Gleevec antitrust suits against Novartis, after failing initially, fall short again in appeals

After a yearslong court battle, Novartis has prevailed against a pair of class-action lawsuits alleging the company illegally protected its blockbuster leukemia drug Gleevec with "sham" patent litigation.